International expert Professor Jan Burger from the MD Anderson Cancer Center in Houston, Texas shared his thoughts on the treatment options in relapsed/refractory chronic lymphocytic leukaemia (CLL) with delegates attending Janssen’s H3 medical education symposium in Melbourne. “We’ve relied on chemo-immunotherapy (CIT) for salvage for some time, but overall the outcome is not good in ...
With choice comes challenge – how do we know what to choose and when in CLL?
26 Aug 2019
Sponsored by Janssen-Cilag Pty Ltd